Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACD440 in peripheral neuropathic pain
NCT05416931Phase 2Completed
- Sponsor
- AlzeCure Pharma
- Start
- Jun 2022
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Peripheral neuropathic pain comparing ACD440 Gel with Placebo Gel (2 arms). Primary endpoint: Stimulus evoked pain at Day 7. Started Jun 2022; status: completed.
02
Drugs
acd440
03
Conditions
Peripheral neuropathic pain
Beyond the preview
Go deeper on NCT05416931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05416931.